1. Home
  2. GIPR vs IMRN Comparison

GIPR vs IMRN Comparison

Compare GIPR & IMRN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Generation Income Properties Inc.

GIPR

Generation Income Properties Inc.

HOLD

Current Price

$0.81

Market Cap

6.4M

Sector

Real Estate

ML Signal

HOLD

Logo Immuron Limited

IMRN

Immuron Limited

HOLD

Current Price

$1.01

Market Cap

12.0M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
GIPR
IMRN
Founded
2015
1994
Country
United States
Australia
Employees
N/A
N/A
Industry
Real Estate Investment Trusts
Biotechnology: Pharmaceutical Preparations
Sector
Real Estate
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
6.4M
12.0M
IPO Year
2021
N/A

Fundamental Metrics

Financial Performance
Metric
GIPR
IMRN
Price
$0.81
$1.01
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
63.6K
84.6K
Earning Date
11-17-2025
02-27-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$9,953,920.00
$4,777,422.00
Revenue This Year
$1.12
N/A
Revenue Next Year
$0.52
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
48.63
52 Week Low
$0.63
$0.68
52 Week High
$2.06
$2.39

Technical Indicators

Market Signals
Indicator
GIPR
IMRN
Relative Strength Index (RSI) 52.02 46.68
Support Level $0.71 $0.93
Resistance Level $0.88 $1.05
Average True Range (ATR) 0.07 0.10
MACD 0.02 0.03
Stochastic Oscillator 75.47 40.56

Price Performance

Historical Comparison
GIPR
IMRN

About GIPR Generation Income Properties Inc.

Generation Income Properties Inc is an internally managed real estate investment company focused on acquiring and managing income-producing retail, office and industrial properties net leased to high-quality tenants in markets throughout the United States. Its key source of revenue is the rental income. The company holds properties in Alabama, Arizona, Colorado, the District of Columbia, Florida, Illinois, North Carolina and Virginia.

About IMRN Immuron Limited

Immuron Ltd is a commercial and clinical-stage biopharmaceutical company with a proprietary technology platform focused on polyclonal antibodies that can address unmet medical needs. The company's commercial products are: Travelan (an orally administered passive product indicated to reduce the risk of travelers' diarrhea and minor gastrointestinal disorders), and Protectyn, which is marketed as an immune supplement. Additionally, it has two clinical products in development, IMM124-E and IMM529, for the treatment of multiple high-value enteric disease indications. The firm has two reportable segments: Hyper-immune products, which derive maximum revenue, and Research and development. Geographically, the company generates maximum revenue from Australia, followed by the USA and Canada.

Share on Social Networks: